Adverum Biotechnologies
ADVM
ADVM was delisted on the 8th of December, 2025.
50 hedge funds and large institutions have $63.8M invested in Adverum Biotechnologies in 2025 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 23 reducing their positions, and 14 closing their positions.
112% more capital invested
Capital invested by funds: $30.1M → $63.8M (+$33.6M)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
0% more ownership
Funds ownership: 67.06% → 67.07% (+0%)
14% less funds holding
Funds holding: 58 → 50 (-8)
35% less call options, than puts
Call options by funds: $196K | Put options by funds: $301K
57% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 14
70% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$2.97M |
| 2 |
Two Sigma Investments
New York
|
+$206K |
| 3 |
PWA
Principia Wealth Advisory
Dallas,
Texas
|
+$144K |
| 4 |
Two Sigma Advisers
New York
|
+$80.7K |
| 5 |
Vanguard Personalized Indexing Management
Oakland,
California
|
+$37.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$611K |
| 2 |
TCM
TCG Crossover Management
Palo Alto,
California
|
-$378K |
| 3 |
BlackRock
New York
|
-$304K |
| 4 |
Goldman Sachs
New York
|
-$279K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$180K |
ADVM Hedge Fund Activity: Q3 2025 in Review
50 of the 7,641 institutional investors tracked by Wall St. Rank reported a position in Adverum Biotechnologies (ADVM) for Q3 2025, worth a combined $63.8M — up 112% from $30.1M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of ADVM and 6 opened new positions — a net loss of 8 holders — while 23 trimmed existing stakes and 7 added.
The largest buyer was Frazier Life Sciences Management, adding an estimated $2.97M. The largest seller was Renaissance Technologies, cutting an estimated $611K.
- 50 institutional investors held Adverum Biotechnologies (ADVM) as of Q3 2025, down from 58 in Q2 2025.
- Funds reported $63.8M of Adverum Biotechnologies stock for Q3 2025, up 112% quarter-over-quarter.
- 6 funds opened new Adverum Biotechnologies positions in Q3 2025 and 14 closed out, a net change of -8 holders.
- The largest Adverum Biotechnologies buyer in Q3 2025 was Frazier Life Sciences Management, an estimated $2.97M added.
- The largest Adverum Biotechnologies seller in Q3 2025 was Renaissance Technologies, an estimated $611K sold.
Based on aggregated 13F filings for Q3 2025.